Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 17000
Country/Region: Ethiopia
Year: 2016
Main Partner: Tigray Regional Health Bureau - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $4,524,745 Additional Pipeline Funding: $150,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $671,341
Care: TB/HIV (HVTB) $191,812
Care: Pediatric Care and Support (PDCS) $108,182
Laboratory Infrastructure (HLAB) $80,087
Strategic Information (HVSI) $77,867
Health Systems Strengthening (OHSS) $67,056
Biomedical Prevention: Blood Safety (HMBL) $15,309
Testing: HIV Testing and Counseling (HVCT) $65,496
Sexual Prevention: Other Sexual Prevention (HVOP) $73,328
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $211,137
Treatment: Adult Treatment (HTXS) $2,656,231
Treatment: Pediatric Treatment (PDTX) $306,899
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 281
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 232
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 294
GEND_GBV Number of people receiving post-GBV care 2017 527
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 39,246
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 40,504
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 274,220
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 118,502
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 472,472
HTS_TST Service Delivery Point (Facility): Inpatient 2017 36,936
HTS_TST Service Delivery Point (Facility): Other PITC 2017 24,611
HTS_TST Service Delivery Point (Facility): Outpatient 2017 141,584
HTS_TST Service Delivery Point (Facility): PMTCT 2017 164,670
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 27,700
HTS_TST Service Delivery Point (Facility): VCT 2017 76,972
HTS_TST Sum of Aggregated Age/Sex <15 2017 79,750
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 392,722
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 472,472
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 337
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 332
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 4,232
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,716
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 1,940
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 1,940
KP_PREV Total estimated number of key population in the catchment area 2017 5,151
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 5,151
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 13
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 13
LAB_PT CD4: Number of laboratories that perform this testing 2017 19
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 167
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 167
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 167
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 63
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 63
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 167
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 3
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 7
PMTCT_ART Already on ART at beginning of current pregnancy 2017 980
PMTCT_ART New on ART 2017 665
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 147,861
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,440
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 364
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 13
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 23
PMTCT_EID Sum of Infant Age disaggregates 2017 1,804
PMTCT_STAT By: Known positives at entry 2017 1,221
PMTCT_STAT By: Number of new positives identified 2017 659
PMTCT_STAT Number of new ANC and L&D clients 2017 158,157
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 147,861
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,880
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 10,057
PP_PREV Total number of people in the target population 2017 613
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 8
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 177
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 16
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 277
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 477
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 477
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,852
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 863
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 854
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 1,135
TB_SCREENDX Screen Result: Screened Positive for TB 2017 4,063
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 1
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 24,404
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 13,345
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 1,426
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 1,542
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 1
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 40,717
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 473
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,975
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 628
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,754
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 7,830
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 8,106
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,426
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,552
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1
TX_CURR Aggregated Age/Sex: 15+ Female 2017 25,872
TX_CURR Aggregated Age/Sex: 15+ Male 2017 13,863
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 1
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 42,713
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,978
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 1
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 39,735
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 1
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 42,713
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 389
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 389
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 3,771
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,898
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 6,448
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 6,447
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 27,645
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 22,128
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 762
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 826
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 13,397
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 7,143
TX_PVLS Numerator: Indication: Routine 2017 17,709
TX_PVLS Numerator: Indication: Targeted 2017 4,419
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 947
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,027
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 16,737
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 8,934
TX_PVLS_den Denominator: Indication: Routine 2017 22,113
TX_PVLS_den Denominator: Indication: Targeted 2017 5,530
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 131
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 159
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,572
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 875
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,737
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 3,076
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 151
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 177
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,770
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 982
Cross Cutting Budget Categories and Known Amounts Total: $659,680
Food and Nutrition: Policy, Tools, and Service Delivery $87,274
Renovation $289,864
Motor Vehicles: Purchased $200,000
Key Populations: Sex Workers $39,331
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $43,211
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation